Synaffix expands into DNA sequencing through a strategic licensing agreement with Illumina, bringing its metal-free click chemistry technology to next-gen sequencing solutions.

Neuer Milliarden-Deal in der ADC-Welt: Lonzas ADC-Spezialunternehmen Synaffix gewinnt Boehringer Ingelheim als neuen Partner für die Bereitstellung der ADC-Technologieplattform in einem Deal im Wert von bis zu 1,3 Mrd. US-Dollar.

Agreement grants access to Synaffix patent portfolio related to metal-free click chemistryTechnology to be used in Illumina's next-generation sequencing (NGS) productsAMSTERDAM, Dec. 4, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index and beyond, today announced it has entered into a licensing agreement with Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies. The agreement grants Illumina access to Synaffix's patented metal-free click chemistry technology.Synaffix's patented metal-free click chemistry will be used in relation to certain Illumina

Neuer Milliarden-Deal in der ADC-Welt: Lonzas ADC-Spezialunternehmen Synaffix gewinnt Boehringer Ingelheim als neuen Partner für die Bereitstellung der ADC-Technologieplattform in einem Deal im Wert von bis zu 1,3 Mrd. US-Dollar.

Patent surprise ends ABL Bio’s ADC deal with IntoCell, shifts focus to Synaffix  koreabiomed.com

Lonza and Sidewinder Therapeutics have partnered to develop innovative bispecific antibody-drug conjugates (ADCs) aimed at treating solid tumors, leveraging advanced ADC technology.

Lonza's Synaffix collaborates with Qurient Therapeutics to advance dual-payload ADCs aimed at targeting tough cancers, marking a significant step in medical innovation.

Boehringer Ingelheim boosts its oncology portfolio by licensing innovative ADC technology from Synaffix, aiming to enhance cancer treatment outcomes.

Synaffix partners with Mitsubishi Tanabe Pharma to utilize cutting-edge ADC technologies, enhancing drug efficacy and patient outcomes.

Elevation Oncology has secured a licensing agreement with Synaffix for innovative ADC technology to boost their drug development pipeline targeting solid tumors.

Synaffix has entered into a licensing agreement with Illumina to enhance DNA sequencing technology using its patented metal-free click chemistry, aiming for improved therapeutic applications.

Elevation Oncology advances cancer treatment with new HER3 ADC candidate EO-1022, leveraging proven antibody tech and Synaffix platform for breast, lung, and pancreatic cancers.

License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix's exatecan-based technology with Qurient's CDK7 inhibitor AMSTERDAM and SEONGNAM-SI, South Korea , Sept. 25, 2025 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN)...

-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – -- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan…

Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix's proprietary ADC…

Agreement grants access to Synaffix patent portfolio related to metal-free click chemistry Technology to be used in Illumina's next-generation sequencing (NGS) products AMSTERDAM, Dec. 4, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX:LONN)…

Lonza’s Synaffix has secured two separate licensing deals with Boehringer Ingelheim and Japanese drugmaker Mitsubishi Tanabe Pharma for its antibody-drug conjugate tech. The two “long-term” deals were announced Thursday. While details are sparse,…